IL-12 p40

Assets acting on this target.

Class
IL-12/23 inhibitor
Pathway
IL-12 / Th1

IL-12 p40 is a protein subunit shared by two related cytokines, interleukin-12 (IL-12) and interleukin-23 (IL-23). Cytokines are small signaling proteins that immune cells use to communicate. IL-12 and IL-23 each pair the p40 subunit with a distinct partner subunit, and together they direct the maturation of T helper cells into two functionally distinct populations: Th1 cells, which coordinate defense against intracellular pathogens, and Th17 cells, which are implicated in inflammation at epithelial surfaces such as skin and gut lining. In several chronic inflammatory and autoimmune diseases, these pathways become persistently overactive, driving tissue damage. Because p40 is a structural component common to both cytokines, an antibody that binds and neutralizes p40 blocks IL-12 and IL-23 signaling simultaneously, rather than targeting either pathway alone. This dual interruption addresses conditions where both Th1- and Th17-driven inflammation contribute to disease, such as certain forms of psoriasis, psoriatic arthritis, and inflammatory bowel disease. The therapeutic rationale is that suppressing this upstream shared node reduces the downstream inflammatory cascade at its source, rather than addressing individual downstream effector molecules separately. This approach exemplifies how targeting a shared building block of related cytokines can achieve broader pathway modulation than a single-cytokine-specific agent.

By indication

Related mechanisms

IL-12 p40 drugs compared

8 drugs, stage by indication
8 drugs acting on IL-12 p40: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
ustekinumabStelaraJohnson & Johnsonmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis
ustekinumab-aauz (Otulfi)OtulfiFormycon AG, Fresenius SE & Co. KGaANot recordedApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis
ustekinumab-aekn (Selarsdi)SelarsdiAlvotech, STADA Arzneimittel, Teva Pharmaceutical Industriesmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis
ustekinumab-auub (Wezlana)WezlanaAmgenmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis
ustekinumab-hmny (Starjemza)StarjemzaBio-Thera Solutions, Gedeon Richter, Hikma Pharmaceuticals PLCmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis
ustekinumab-srlf (Imuldosa)ImuldosaAccord BioPharma Inc., Accord Healthcare, Dong-A ST, Meiji Seika Pharmamonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis
ustekinumab-stba (Steqeyma)SteqeymaCelltrionmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis
ustekinumab-ttwe (Pyzchiva)PyzchivaOrganon, Samsung Bioepis, Sandoz Group AGmonoclonal antibodyApprovedApproved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis

← all mechanisms